Enzymes Global Market Report 2023 – By Product Type (Asparginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products), By Application (Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications), By End User (Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories) – Market Size, Trends, And Global Forecast 2023-2032

Healthcare Specialty Enzymes Market Definition

Digestive enzymes refer to compounds that aid in digestion by assisting with food breakdown. These proteins accelerate the chemical processes that transform food into compounds that can be absorbed by the digestive system. The salivary glands and the cells lining the stomach, pancreas, and small intestine produce (release) them. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas, a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores. The global digestive enzymes market is segmented - 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores The global digestive enzymes market size grew from $0.82 billion in 2022 to $0.89 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global digestive enzymes is expected to grow from $1.32 billion in 2027 at a CAGR of 10.3%. The rising prevalence of gastrointestinal disorder among different age groups drives the growth of the digestive enzymes market. Gastrointestinal disorders include disorders in the gastrointestinal tract starting from the mouth, oesophagus, stomach, small intestine, large intestine, and anus caused due to lack of digestive enzymes. Gastrointestinal disorders require the digestive enzymes to be taken orally as a dietary supplement or as a drug. The increased rates of gastrointestinal disorders are linked to smoking, diet and genetics, sanitation, increased use of antibiotics, and the changing environmental factors due to industrialization and urbanization. According to the American Gastroenterological Association’s survey published in April 2020 on the worldwide prevalence and burden of functional gastrointestinal disorders, among 73,076 adult respondents, about 40.3% of people met the diagnostic criteria for at least 1 functional gastrointestinal disorder (FGIDs). FGID was more prevalent among women than men. A large-scale multinational study found that more than 40% of the population is having FGIDs across the globe. Therefore, the increase in the prevalence of digestive diseases contributes to the growth of the digestive enzymes market. Major players in the digestive enzymes market are Garden of Life, Biotics Research Corporation, Klaire Laboratories, Abbott Nutrition, AbbVie Inc., Allergan PLC., Johnson & Johnson Inc. Amway Corporation, Food State Inc., Matsun Nutrition, Metagenics Inc., Twinlab Corporation, Food State Inc., AST Enzymes, VEMO 99 OOD, Advanced Vital Enzymes Pvt. Ltd., Zeus Biotech Limited, Vox Nutrition Inc., Enzyme Bioscience Pvt. Ltd., Metagenics, XYMOGEN Inc., Douglas Laboratories, Thorne Research, Integrative Therapeutics LLC., Pure Encapsulations, Ortho Molecular Products Inc., Designs for Health Inc., Master Supplements Inc., and Proteozymes. The potential side effects of digestive enzyme supplements and drugs restrain the growth of the digestive enzymes market. Continuous intake of digestive enzymes increases dependency on the digestive enzymes resulting in a weaker digestive system over time. The weakened digestive system leads to digestive distress, gas, nausea, bloating, decreased stomach acid, and allergic reactions accompanied by diarrhea and vomiting. For instance, the digestive enzyme bromelain causes thinning of the blood and increases the risk of excess bleeding. The thinning of the blood is the result of the anti-platelet activity caused by the drug. Thus, the side effects caused by the excess and continuous intake of digestive enzymes negatively impact the growth of the digestive enzymes market. The companies in the digestive enzymes market are investing in developing customized digestive enzymes. These customized digestive enzymes are condition-specific enzymes to support digestion for digestive sensitive patients and may contain multiple enzymes in the same product. The companies involved in manufacturing digestive enzymes are developing customized digestive enzymes to ease the digestion of different types of food. For instance, Sabinsa, a USA-based provider of herbal extracts, cosmeceuticals, minerals, and dietary supplements, formulated DigeZyme. DigeZyme is a multi-enzyme complex comprising five different enzymes, namely, cellulase, lactase, amylase, lipase, and protease. It is widely used by people who have difficulty in digesting carbohydrates, fats, and proteins, respectively. The companies are increasingly investing in developing customized digestive enzymes. In January 2020, Nestlé, a Switzerland-based food and drink processing corporation, entered into an asset purchase agreement with Allergan, an Ireland-based pharmaceutical company that acquires, develops, and markets brand name drugs, to acquire Zenpep for an amount undisclosed. Through the acquisition, Nestle aims to expand its medical nutrition portfolio by including Zenpep products to support food ingestion, digestion, and absorption. Zenpep is a medication for people who cannot digest food properly due to the lack of digestive enzymes. North America was the largest region in the digestive enzymes market in 2022. Middle East is expected to be the largest growing region in the digestive enzymes market report during the forecast period. The regions covered in the digestive enzymes analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digestive enzymes market consists of sales of amylase, maltase, and lactase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The digestive enzymes market research report is one of a series of new reports from The Business Research Company that provides digestive enzymes market statistics, including digestive enzymes industry global market size, regional shares, competitors with a digestive enzymes market share, detailed digestive enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the digestive enzymes industry. The digestive enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Specialty enzymes refer to proteins that have the ability to operate as very selective biocatalysts to speed up reactions and create the required target molecule in medicines. Specialty enzymes are important in a wide range of treatment modalities and applications, most frequently for modification but also to lower viscosity and hence enhance processability and to connect and detach cells, which increases productivity. The main types of specialty enzymes market are carbohydrases, proteases, lipases, polymerases & nucleases, oxidases and hydratases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include microorganisms, animals, and plants and are used in pharmaceutical, diagnostics, research and biotechnology, food and beverage, animal nutrition, and others. The global specialty enzymes market is segmented - 1) By Type: Carbohydrases, Proteases, Lipases, Polymerases & Nucleases, Oxidase & Hydratases, Other Types 2) By Source: Microorganisms, Animals, Plants 3) By Application: Pharmaceutical, Diagnostics, Research & Biotechnology, Food & Beverage, Animal Nutrition, Other Applications The global specialty enzymes market size grew from $5.57 billion in 2022 to $5.97 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The specialty enzymes market size of global specialty enzymes is expected to grow from $7.8 billion in 2027 at a CAGR of 6.9%. Growing investment in biotechnology research and development is expected to boost market growth during the forecast period. Specialty enzymes are widely used in biotech research and development, particularly in molecular biology. The increasing investment and an increase in the number of companies conducting biotechnology research and development will in turn increase the number of biotech researchers. For instance, in April 2021, according to a report published by the Congressional Budget Office, a US-based government agency that provides budget and economic information, pharmaceutical companies will have invested $83 billion on research and development activities around the world. According to the Assobiotec publication BioInItaly 2020, healthcare is involved in 49% of the over 700 biotech firms headquartered in Italy. As a result of increased investment in biotech R&D, the growing number of biotech research companies is expected to boost the specialty enzymes market. Major players in the specialty enzymes market are BASF SE, Novozymes A/S, Roche Holding AG, Codexis Inc., Specialty Enzymes & Probiotics, Advanced Enzyme Technologies Ltd., BBI Solutions, E. I. du Pont de Nemours and Company, Sanofi, and Amano Enzyme Inc. Ethical and societal issues are factors that will slow down the market's growth during the forecast period. The clashing public opinions on these issues will determine the acceptability of new industrial biotechnology products. In 2019, a published article stated that there are five societal and ethical themes concerning industrial biotechnology, namely sustainability, naturalness, risk management, innovation trajectories, and economic justice. Many critics state that the factor affecting economic justice is that the applications of industrial biotechnology lead to the concentration of knowledge and power in the hands of a few companies. Thus, societal and ethical issues are expected to impact market growth. Technological advancements show opportunities for the production of enzyme products more efficiently. Challenges such as complexity in maintaining pH, the operational high temperature of specialty enzymes, and the significant cost of maintenance of specialty enzyme products pave the way for technological advancements. For instance, in February 2020, DuPont Nutrition Biosciences ApS, a Denmark based company specialising in the development, manufacturing, and sale of ingredients for food and beverages, enzymes, and bio-based products, launched the POWERBake enzyme based on its emulsification technology. The enzymes give bakeries and improvement centers a special emulsification solution that satisfies consumer expectations for cleaner labelling while maintaining the flavour and quality of white breads and buns. In May 2021, BRAIN AG, a Germany-based industrial biotechnology company that identifies and develops innovative solutions and products for use in the chemistry, cosmetics, and food industries, paid $ 5.51 million (GBP 3.9 million) for additional shares in Biocatalysts Ltd.The acquisition further strengthens BRAIN’s BioIndustrial segment and widens commercial opportunities with Biocatalyst's portfolio and technology, including access to BRAIN’s unique BioArchive and Biocatalyst’s MetXtra metagenomic library. Biocatalysts Ltd. is a UK-based manufacturer of specialty enzymes that focuses on the use of technology to develop novel specialty enzymes cost-effectively. North America will be the largest region in the viral specialty enzymes market in 2022. Middle East is expected to be the fastest growing region in the specialty enzymes market report during the forecast period. The regions covered in the specialty enzymes analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The specialty enzymes market consists of sales of acylases, hydratases, humulin oxidase, and lyases. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The countries covered in the specialty enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The specialty enzymes market research report is one of a series of new reports from The Business Research Company that provides specialty enzymes market statistics, including specialty enzymes industry global market size, regional shares, competitors with a specialty enzymes market share, detailed specialty enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the specialty enzymes industry. This specialty enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Diagnostic enzymes refer to the enzymes that are employed directly or as part of an assay system to determine the presence or absence of a variety of compounds, and they are used to detect, diagnose, or predict the development of disease conditions. These enzymes are used in diagnosis because of their substrate selectivity and quantified activity when other proteins are present. The main types of products in the diagnostic enzymes market are carbohydrates, polymerases, nucleases, proteases, and others. Any of a class of enzymes (such as amylase) that promotes carbohydrate breakdown or synthesis is referred to as a carbohydrase (such as a disaccharide). The different sources include animals, microorganisms, and plants and are used in biocatalysts, diagnostics, pharmaceuticals, research, and biotechnology. The global diagnostic enzyme market is segmented - 1) By Product Type: Carbohydrases, Polymerases And Nucleases, Protease, and Other Product Types 2) By Source: Animals, Microorganisms, and Plants 3) By Application: Biocatalysts, Diagnostics, Pharmaceuticals, Research, and Biotechnology The global diagnostic enzymes market size grew from $3.8 billion in 2022 to $4.02 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global diagnostic enzymes is expected to grow from $5.1 billion in 2027 at a CAGR of 6.1%. The rise in the geriatric population, which increases the patient pool for the diagnosis of chronic diseases, contributed to the growth of the diagnostic enzymes market. The proportion of people above the age of 65 increased globally, and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% by 2050 in Japan. The increase in the ageing population has increased the patient pool of many chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly influencing market growth during this period. According to the World Population Ageing report, there were 727 million people over the age of 65 in 2020, accounting for 9.3% of the global population, and this figure is expected to rise to around 16.0% by 2050.According to the World Health Organization report for 2021, approximately 10 million cancer-related deaths occurred in 2020. Thus, the rise in the geriatric population increases the number of patients for the diagnosis of chronic diseases, which, in turn, drives the diagnostic enzymes market. Major players in the diagnostic enzymes market are Genzyme, Roche, Codexis, Aldevron, Kaneka Eurogentec, Vigene Biosciences, Amano Enzymes, Advanced Enzymes Technologies, Thermo Fisher Scientific, and EKF Diagnostic. The high sensitivity of enzymes to temperature and pH levels is expected to limit the diagnostic enzymes market. Enzymes need to be stored at optimum temperatures and are generally stored at -20 degrees Celsius. According to the Worthington Biochemical Corporation, variations in the reaction by one or two degrees in temperature may have a change of 10 to 20% in the result. In enzymatic reactions, this is complicated as enzymes are adversely affected by high temperatures, and are expected to be deactivated at even moderate temperatures. Enzymes are affected by changes in pH, as pH is also a factor in the stability of the enzymes. The changes in temperature and pH levels may decrease the efficiency of the diagnostic enzymes, which, in turn, hampers the growth of the diagnostic enzymes market. The use of machine learning and artificial intelligence is gradually gaining popularity in the enzyme diagnostic market. Artificial intelligence (AI) is the simulation of human intelligence in machines and is programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the enzyme diagnostic market to conduct a detailed analysis of all relevant data, provide insights into the function of enzymes, and allow physicians to understand the key determinants of the relationship between protein structure, function, and evolution, in terms of the catalysis of the reaction steps of an enzyme. For instance, companies such as BioMarker have invested in AI and machine learning for enzyme diagnostics. In June 2020, Codexis, Inc., a US-based protein engineering company and developer of high-performance enzymes, and Alphazyme LLC., a US-based company in the development and manufacture of nucleic acid metabolising enzymes, announced a co-marketing enzyme supply collaboration agreement for the production and co-marketing of enzymes for life science applications, including diagnostics. This collaboration is expected to leverage the experience and industry knowledge of Alphazyme to accelerate the market introduction of Codexis’ portfolio of high-performing life science and diagnostic enzymes while providing Alphazyme with exclusive manufacturing and co-marketing rights to CodeEvolver-improved enzymes. This partnership will allow both companies to jointly promote and sell these enzymes to innovators in life science and diagnostic markets. North America was the largest region in the enzymes market in 2022. Middle East is expected to be the fastest-growing region in the diagnostic enzyme market report during the forecast period. The regions covered in the diagnostic enzymes analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the diagnostic enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The diagnostic enzymes market consists of sales of acid phosphatase, alanine aminotransferase, cholinesterase, and aspartate aminotransferase. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in the diagnostic enzymes market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The diagnostic enzymes market research report is one of a series of new reports from The Business Research Company that provides diagnostic enzymes market statistics, including global market size, regional shares, competitors with a diagnostic enzymes market share, detailed diagnostic enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic enzymes industry. The diagnostic enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Synthetic Biology Market Definition

Enzyme inhibitor refers to a chemical that inhibits an enzyme's activity. Enzymes participate in a variety of cell processes, including cell signalling, growth, and division, as well as accelerating chemical reactions in the body. Enzymes help to speed up chemical reactions in the body and take part in many cell functions, including cell signaling, growth, and division. The main types of enzyme inhibitors are proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, aromatase inhibitors, kinase inhibitors, neuraminidase inhibitors, statins, and other types. Proton pump inhibitors refer to medicines that work by decreasing the amount of stomach acid made by glands in the lining of the stomach. The various disease indications include chronic obstructive pulmonary disorders, cardiovascular disease, gastrointestinal disorders, arthritis, inflammatory diseases, and others. The enzyme inhibitors are applicable in chemotherapy, antibiotics, pesticides, cardiovascular treatments, and others and are used in pharmaceuticals, biotechnology, food and beverage, and other end users. The global enzyme inhibitor market is segmented - 1) By Type: Proton Pump Inhibitors (PPIs), Protease Inhibitors, Reverse Transcriptase Inhibitors, Aromatase Inhibitors, Kinase Inhibitors, Neuraminidase Inhibitors, Statins, Other Types 2) By Disease Indication: Chronic Obstructive Pulmonary Disorders, Cardiovascular Disease, Gastrointestinal Disorders, Arthritis, Inflammatory Diseases, Other Disease Indications 3) By Application: Chemotherapy, Antibiotics, Pesticides, Cardiovascular Treatments, Other Applications 4) By End User: Pharmaceutical, Biotechnology, Food and Beverage, Other End Users The global enzyme inhibitor market size will grow from $173.2 billion in 2022 to $177.82 billion in 2023 at a compound annual growth rate (CAGR) of 2.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of thr enzyme inhibitor is expected to grow to $196.29 billion in 2027 at a CAGR of 2.5%. The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, according to the World Health Organization, 19.3 million new cancer cases were registered, and almost 10.0 million cancer deaths occurred in 2020. In addition, there were more than 1.6 million people diagnosed with cancer in the US. Therefore, the rise in the incidence of diseases like cancer is driving the demand for the enzyme inhibitor market growth. Major players in the enzyme inhibitor market are Abbott Laboratories, Amgen Inc., AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, Pfizer Inc., Ranbaxy Laboratories, Takeda Pharmaceutical Company, Merck and Co. Inc., Eli Lilly and Company, Bristol Myers Squibb, Cipla USA Inc., AbbVie, Teva Pharmaceutical Industries Ltd., and Janssen Pharmaceuticals. Strategic partnerships and collaborations have emerged as a key trend gaining popularity in the enzyme inhibitor market. Major companies operating in enzyme inhibitors are focused on strategic partnerships to meet customer demand. For instance, in April 2021, Artios Pharma Limited, a UK-based DNA damage response company that also provides enzyme inhibitors, collaborated with Novartis International AG, a Switzerland-based pharmaceutical corporation, to uncover and verify new generation DDR (DNA Damage Response) targets to advance Novartis' Radioligand Therapies (RLT). This partnership with Novartis will be utilized to find and validate next-generation DDR targets to improve Novartis' radioligand therapies. Furthermore, in March 2020, Bayer AG, a Germany-based pharmaceutical and life sciences company, collaborated with Curadev, an Indian-based pharmaceutical company that provides enzyme inhibitors, to discover new drug candidates to provide treatment for lung diseases, cardiovascular diseases, and other inflammatory diseases. In March 2021, Amgen Inc., a US-based biotechnology company, acquired Rodeo Therapeutics Corporation for a deal amount of $666 million. Through this acquisition, Rodeo is focused on developing first-in-class, orally available modulators of prostaglandin biology that play an important role in tissue regeneration and repair. Rodeo Therapeutics Corporation is a US-based biopharmaceutical company that develops enzyme inhibitors. North America was the largest region in the enzyme inhibitor market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enzyme inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the enzyme inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The enzyme inhibitor market consists of sales of competitive, noncompetitive, and uncompetitive inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The enzyme inhibitors market research report is one of a series of new reports from The Business Research Company that provides enzyme inhibitors market statistics, including enzyme inhibitors industry global market size, regional shares, competitors with an enzyme inhibitors market share, detailed enzyme inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme inhibitors industry. This enzyme inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Animal growth promoters and performance enhancers refer to the substances that are added to feeds as supplements or injections to increase feed utilization and growth in farm animals, as well as veterinary medicinal products that are administered to healthy animals in order to favourably influence the yield, quality, and/or growth of animal products. The main types of animal growth promoters and performance enhancers are antibiotic growth promoters and non-antibiotic growth promoters. Antibiotic growth promoters refer to the promoters that will enhance the health of the animal and increase productivity. These include natural chemicals such as microbial products, prebiotics, and probiotics, yeast products, enzymes and herbs, oils, and spices. The different types of animals that use animal growth promoters and performance enhancers include poultry, swine, livestock, aquaculture, and other animals. The global animal growth promoters and performance enhancers market is segmented – 1) By Type: Antibiotic Growth Promoters, Non-Antibiotic Growth Promoters 2) By Animal Type: Poultry, Swine, Livestock, Aquaculture, Other Animals 3) By Nature of Chemicals: Microbial Products, Prebiotics And Probiotics, Yeast Products, Enzymes/Herbs, Oils And Spices The global animal growth promoters and performance enhancers market size will grow from $13.73 billion in 2022 to $14.65 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global animal growth promoters and performance enhancers market size is expected to grow to $18.92 billion in 2027 at a CAGR of 6.6%. The growing demand for meat is a significant factor that will drive the market for animal growth promoters and performance enhancers. Animal growth promoters make the animal accumulate fat and weight, resulting in more meat production and a more expensive animal. Meat is a major protein source for many people around the world. According to a study by FAO, the production of meat has doubled in the last 30 years and increased four-fold since the mid-1960s. The production and consumption of meat are expected to continue to grow. By 2050, global meat consumption is projected to reach between 460 million and 570 million tons. This is expected to drive the animal growth promoters and performance enhancers market. Major players in the animal growth promoters and performance enhancers market are Merck Animal Health, Cargill, Royal DSM N.V., Vetoquinol S.A., Bupo Animal Health, Elanco Animal Health Inc., Alltech, Bayer Animal Health, Zoetis, and Bioniche Life Sciences. Strict rules set by the US and European governments on the use of animal growth promoters and performance enhancers are restricting the animal growth promoter and performance enhancers market. For instance, Zoetis, the largest producer of animal medicines, is banned from selling antibiotics that promote faster growth in animals in the US and Europe. The US FDA has implemented a regulation that bans the use of antibiotics as feed supplements to help livestock and poultry grow faster. These regulations are expected to negatively impact the growth of the animal growth promoters and performance enhancers market. Companies in the market are increasingly investing in phytogenics for higher efficiency of growth promoters through natural means. Phytogenics, sometimes also referred to as botanicals or phytobiotics, are plant-based feed additives utilised in animal nutrition. They are derived from herbs, spices, and extracts. Phytochemicals can be used in solid, dried, and ground form or as extracts, and can also be classified as essential oils and oleoresins depending on the process used to derive the active ingredients. The use of phytogenics promotes increased feed intake, improved gut function, prevention of diarrhea, and antimicrobial and antioxidative effects in livestock. Companies such as Delacon, Cargill, and BIOMIN have invested in phytogenics. In June 2020, Elanco acquired Bayer Animal Health for $7.6 billion. This acquisition is expected to help Elanco expand its product profile and reach for medicines for pets and livestock. Bayer Animal Health is a division of Bayer HealthCare. North America was the largest region in the animal growth promoters and performance enhancers market in 2022. Asia-Pacific was the second-largest region in the global animal growth promoters and performance enhancers market. The regions covered in the global animal growth promoters and performance enhancers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal growth promoters and performance enhancers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The animal growth promoters and performance enhancers market consists of sales of growth hormone medications, anabolic implants, bovine somatotropin, ß-agonists and probiotics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal growth promoters and performance enhancers report is one of a series of new reports from The Business Research Company that provides animal growth promoters and performance enhancers market statistics, including animal growth promoters and performance enhancers industry global market size, regional shares, competitors with animal growth promoters and performance enhancers market share, detailed animal growth promoters and performance enhancers market segments, market trends and opportunities, and any further data you may need to thrive in the animal growth promoters and performance enhancers industry. This animal growth promoters and performance enhancers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epigenetics is a change in gene activity transmitted to younger cells without modifying the DNA sequence. Epigenetic processes are natural and necessary for many organisms to work, but unusual occurrences can cause disorders, such as various types of cancer, reproductive illnesses, and cardiovascular illnesses. Epigenetics is used detect a type of cancers earlier. The main products used in epigenetics market are reagents, enzymes, instruments and kits. Reagents are compounds or substances that are used for chemical analysis or epigenetic testing. DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification and chromatin structures are the technologies used in epigenetics. The application included oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases and other applications. These epigenetics are used by academic and research institutes, pharmaceutical, and biotechnology companies, contract research organizations and other end users. The global epigenetics market is segmented - 1) By Product: Reagents, Enzymes, Instruments, Kits 2) By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures 3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications 4) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organisations, Other End Users The global epigenetics market size grew from $7.38 billion in 2022 to $8.85 billion in 2023 at a compound annual growth rate (CAGR) of 20.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global epigenetics is expected to grow to $18.21 billion in 2027 at a CAGR of 19.8%. The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market. The rising prevalence of diseases increases the demand for epigenetics. According to the European Commission's Joint Research Centre from Ispra, the number of new cancer cases in the European Union (EU) and European Free Trade Association (EFTA) countries will rise by 21.4%, from 2.8 million in 2020 to 3.4 million in 2040. Furthermore, according to the Centers for Disease Control and Prevention (CDC), approximately 659,000 people in the United States die of heart disease each year. The increasing prevalence of cancer and other diseases requires testing and knowing the modifications that happened in the genes, which will invariably increase the usage and demand of epigenetics. Thus, the growing prevalence of cancer and other diseases drives the epigenetics market in the coming years. Major players in the epigenetics market are Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode, Hoffmann-La Roche Ltd., Eisai Co Ltd and Novartis AG. Technological advancement is the key trend in the epigenetics market. The key players in the epigenetics sector are focusing on developing various technologically advanced products and services to strengthen their position in the market. For instance, in May 2021, Givaudan Active Beauty, a Switzerland-based company specialising in fragrance, beauty, taste and wellbeing, launched Chronoglow. Chronoglow is a skin-care-beneficial active component created by green fractionation and supported by artificial intelligence (AI) that can replicate natural epigenetic mechanisms. Chronoglow is a natural skin remedy made from Haberlea rhodopensis, often known as the resurrection plant, which can improve the skin's luminosity and reverse the signs of aging. In December 2020, Exact Sciences, a US-based molecular diagnostic company, acquired Base Genomics for $140 million. As a result of this acquisition, Exact Sciences aims to create a multi-cancer early detection blood test. This acquisition also aids in the acceleration of clinical and commercial development. Base Genomics is a UK-based epigenetics company working on designing a blood test for minimal residual disease and early-stage cancer. North America was the largest region in the epigenetics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the epigenetics market during the forecast period. The regions covered in the global epigenetics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The epigenetics market includes revenues earned by entities methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The epigenetics market research report is one of a series of new reports from The Business Research Company that provides epigenetics market statistics, including epigenetics industry global market size, regional shares, competitors with an epigenetics market share, detailed epigenetics market segments, market trends and opportunities, and any further data you may need to thrive in the epigenetics industry. This epigenetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.